News und Analysen
EnWave unterzeichnet Technologieevaluierungs- und Lizenzoptionsvertrag mit führendem europäischen Snack-Unternehmen
Vancouver, B.C., 26. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
IMV to Participate at Four Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
EnWave Corporation Refining Development of a Medical Device to Relieve COVID-19 Symptoms
Vancouver, B.C., August 25, 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), announced
EnWave Corporation Verfeinerungsentwicklung eines medizinischen Geräts zur Linderung der COVID-19-Symptome
Vancouver, B.C., 25. August 2020, Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The
Antibe Therapeutics Announces Results of Annual and Special Meeting
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information
EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update
Vancouver, B.C., August 20th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), a global
EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt Update zu NutraDried
Vancouver, B.C., 20. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), ein
Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology
August 19, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) are pleased to announce the establishment of a joint
Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode
19. August 2018 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, die Gründung eines Joint Ventures („J
Relay Medical and Fio Corporation Extend MOU Agreement for Collaboration on a Rapid Diagnostic Testing Platform
August 16, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) jointly report that the Companies have extended the me
Relay Medical und Fio Corporation verlängern ihre Absichtserklärung bezüglich der Zusammenarbeit im Hinblick auf eine Schnelltest-Diagnoseplattform
16. August 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) berichten gemeinsam, dass die Unternehmen ihre am
IMV Inc. Announces Second Quarter 2020 Financial Results
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
NeutriSci Provides Update Regarding Product Launch in California
Vancouver, British Columbia – August 12, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
NeutriSci: Neuigkeiten zur Produkteinführung in Kalifornien
Vancouver, British Columbia – 12. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) – ein innovatives
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent
Antibe Therapeutics Engages Stern IR for Investor Relations Services
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support
EnWave Signs Commercial License and Equipment Purchase Agreement with Orto Al Sole to use REV™ Technology in Italy
Vancouver, B.C., August 5, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced today
EnWave unterzeichnet kommerziellen Lizenz- und Gerätekaufvertrag mit Orto Al Sole für Nutzung der REV™ Technologie in Italien
Vancouver, B.C., 5. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that
Antibe Therapeutics Provides Corporate Update
Antibe Therapeutics Inc.:
- Phase II secondary data confirmed remarkable potency of ATB-346 -
- 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at
NeutriSci erhält vom japanischen Gesundheitsministerium die finale Produktzulassung
Vancouver, British Columbia – 4. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), ein innovatives
Neutrisci Receives Final Approval from The Japanese Health Ministry
Vancouver, British Columbia – August 4, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious